Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
株式のランク
#3509
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
株価
$3.86
時価総額
$4.88B
変化（1日）
4.10%
変化（1年）
-50.30%
国
CN
取引 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
カテゴリー
Healthcare
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.（603392）の収益
Jun 2026 時点の収益 TTM: $293.29M
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は $293.29M です。2023 年には $778.51M の収益があり、これは 2022 年の $1.62B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. の収益履歴（2013 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $293.29M | -4.66% |
| 2024 | $307.63M | -60.49% |
| 2023 | $778.51M | -51.99% |
| 2022 | $1.62B | 79.23% |
| 2021 | $904.72M | 151.05% |
| 2020 | $360.38M | 111.99% |
| 2019 | $170.00M | 19.00% |
| 2018 | $142.86M | -2.11% |
| 2017 | $145.94M | 20.04% |
| 2016 | $121.57M | 15.98% |
| 2015 | $104.83M | 8.90% |
| 2014 | $96.26M | 17.00% |
| 2013 | $82.27M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 4,204.41% |
US
|
|
| $2.23B | 659.66% |
US
|
|
| $15.74B | 5,268.23% |
AU
|
|
| $6.02B | 1,953.03% |
NL
|
|
| - | - |
CH
|
